Matarin Capital Management LLC Cut Holding in Enanta Pharmaceuticals INC (ENTA) by $5.13 Billion as Share Price Rose

July 13, 2018 - By Richard Doty

Investors sentiment increased to 1.66 in 2018 Q1. Its up 0.08, from 1.58 in 2017Q4. It increased, as 11 investors sold ENTA shares while 45 reduced holdings. 42 funds opened positions while 51 raised stakes. 14.18 million shares or 4.00% more from 13.64 million shares in 2017Q4 were reported. State Of Wisconsin Inv Board has invested 0.01% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Mason Street Ltd Company accumulated 0.01% or 3,985 shares. Ajo LP invested 0.04% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Invesco Limited invested in 473,228 shares. The Texas-based Hbk Invests Limited Partnership has invested 0.02% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Quantbot Tech Lp owns 7,256 shares or 0.05% of their US portfolio. Schwab Charles Investment Management, a California-based fund reported 91,494 shares. Farallon Management Ltd Company holds 0.51% or 915,000 shares. 105 were reported by Daiwa Secs Gp Incorporated. The Illinois-based Northern Trust Corp has invested 0% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Citigroup Inc stated it has 0% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). 1,600 are held by Riverhead Management Llc. Guggenheim Capital Ltd Liability holds 53,219 shares or 0.01% of its portfolio. State Street holds 0.01% or 757,799 shares. Federated Invsts Incorporated Pa has 0% invested in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) for 51 shares.

Since March 19, 2018, it had 0 insider buys, and 7 sales for $10.89 million activity. Luly Jay R. sold $2.65M worth of stock. MELLETT PAUL J also sold $1.81M worth of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) shares.

Matarin Capital Management Llc decreased its stake in Enanta Pharmaceuticals Inc. (ENTA) by 22.11% based on its latest 2018Q1 regulatory filing with the SEC. Matarin Capital Management Llc sold 63,450 shares as the company’s stock rose 25.19% while stock markets declined. The institutional investor held 223,507 shares of the health care company at the end of 2018Q1, valued at $18.08 billion, down from 286,957 at the end of the previous reported quarter. Matarin Capital Management Llc who had been investing in Enanta Pharmaceuticals Inc. for a number of months, seems to be less bullish one the $2.37 billion market cap company. The stock decreased 2.11% or $2.65 during the last trading session, reaching $123.22. About 199,874 shares traded. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has risen 217.72% since July 13, 2017 and is uptrending. It has outperformed by 205.15% the S&P500.

Matarin Capital Management Llc, which manages about $198.00M and $1334.46B US Long portfolio, upped its stake in Vera Bradley Inc. (NASDAQ:VRA) by 32,262 shares to 434,719 shares, valued at $4.61B in 2018Q1, according to the filing. It also increased its holding in Benchmark Electronics Inc. (NYSE:BHE) by 41,453 shares in the quarter, for a total of 497,655 shares, and has risen its stake in Cantel Medical Corp. (NYSE:CMN).

Analysts await Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) to report earnings on August, 6. They expect $0.96 earnings per share, up 318.18 % or $1.40 from last year’s $-0.44 per share. ENTA’s profit will be $18.50 million for 32.09 P/E if the $0.96 EPS becomes a reality. After $0.61 actual earnings per share reported by Enanta Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 57.38 % EPS growth.

More news for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) were recently published by:, which released: “2 Stable and 2 Speculative Biotech Stocks to Buy” on June 15, 2018.‘s article titled: “5 Biotech Stocks That Could Be the Next Amgen” and published on June 27, 2018 is yet another important article.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Ratings Coverage

Among 6 analysts covering Enanta Pharmaceuticals (NASDAQ:ENTA), 2 have Buy rating, 0 Sell and 4 Hold. Therefore 33% are positive. Enanta Pharmaceuticals had 7 analyst reports since February 8, 2018 according to SRatingsIntel. The stock of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) earned “Buy” rating by Oppenheimer on Thursday, June 7. As per Wednesday, April 4, the company rating was maintained by RBC Capital Markets. The firm earned “Hold” rating on Thursday, February 8 by Robert W. Baird. The firm has “Neutral” rating given on Thursday, February 8 by JP Morgan. The firm earned “Hold” rating on Thursday, February 8 by J.P. Morgan.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.